Replicating clinical placebo effects in computational trials: Bridging the gap between in silico and clinical studies

Paula Dominguez-Gomez,Constantine Butakoff,Georg Rast,Borje Darpo,Mariano Vazquez,Jazmin Aguado-Sierra

DOI: https://doi.org/10.1101/2024.10.18.24315721

2024-10-21

Abstract:This study replicates human cardiac safety clinical trials using computational models, which include diurnal hormonal placebo effects, aiming to create fast and efficient drug screening tools to assess QT interval prolongation preclinically. A virtual cardiac population that simulates sex-specific electrophysiological variability influenced by diurnal hormonal cycles was created to closely mirror human physiology. The goal is to assess the impact of these hormone dynamics on placebo-induced responses and evaluate the virtual population's accuracy in reflecting clinical trial outcomes. The study showed that the virtual population model successfully replicated about 50% of the observed QT variability seen in placebo groups. The computational framework facilitated direct comparison with human clinical trials, achieving critical concentrations, i.e., concentrations that cause a mean QTc effect of 10 ms, within a 0.6-fold range of clinical results. Additionally, the exposure-response slopes exhibited relative errors averaging 43%, which translates into mean absolute errors of 6-7 ms in comparison to clinical data. These results highlight its potential to reproduce human physiology and provide results consistent with real-world human clinical trials. Additionally, a comparison with a previously published statistical placebo model further supports this approach. By approximating the diurnal hormonal variations, as a component of the mechanistic basis of placebo, this method offers a robust decision-making tool for early-stage drug safety assessment.